Board member Michael Schmertzler sold 20,000 PTC Therapeutics shares on 16 and 17 September at prices between $66.58 and $68.45.
PTC Therapeutics (PTCT) director Michael Schmertzler sold 20,000 common shares in open-market transactions on 16 and 17 September, according to a Form 4 filed with the Securities and Exchange Commission. The combined value of the sales was roughly $1,349,728.
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.
